The latest Federation of Obstetric and Gynecological Societies of India (FOGSI) recommendations released in 2025 using the latest guidelines advocated by FIGO, WHO and FOGSI recommend, “If oxytocin is unavailable or its quality cannot be guaranteed, the use of other injectable uterotonics, including carbetocin (heat stable) 100 microgram IM/IV is recommended for the prevention of PPH” [12]. Here, OXT is linked to pulmonary arterial hypertension.